Table 4 Group IV, cases diagnosed with mixed surface epithelial carcinomas
From: Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience
Case no. | HER2/neu | Primary site | Histopathology diagnosis | ||||
|---|---|---|---|---|---|---|---|
IHC | FISH | Result | Type | FIGO | Nuc | ||
1 | 2+ | 7.41 | POS | Endometrium | CCCA + SCA | 3 | 3 |
2 | 1+ | 1.02 | NEG | Ovary | CCCA + SCA | 3 | 3 |
3 | 0 | 1.37 | NEG | Pelvic mass | CCCA + SCA | 3 | 3 |
4 | 0 | NP | NEG | Ovary | CCCA + SCA | 3 | 3 |
5 | 0 | NP | NEG | Ovary | CCCA + SCA | 3 | 3 |
6 | 0 | NP | NEG | Ovary | CCCA + SCA | 3 | 3 |
7a | 0–3+ | 1.38 | NEG | Endometrium | CCCA + SCA | 3 | 3 |
8 | 1+ | 0.93 | NEG | Endometrium | CCCA + ENAdCA | 3 | 3 |
9 | 1+ | NP | NEG | Endometrium | CCCA + ENAdCA | 3 | 3 |
10 | 1+ | NP | NEG | Endometrium | CCCA + ENAdCA | 3 | 3 |
11 | 0 | NP | NEG | Ovary | CCCA + ENAdCA | 3 | 3 |
12 | 1+ | NP | NEG | Ovary | CCCA + ENAdCA | 3 | 3 |
13 | 0 | NP | NEG | Ovary | CCCA + ENAdCA | 3 | 3 |
14 | 0 | NP | NEG | Endometrium | SCA + ENAdCA | 3 | 3 |
15 | 1+ | NP | NEG | Ovary | SCA + ENAdCA | 3 | 3 |
16 | 0 | NP | NEG | Peritoneum | SCA + ENAdCA | 3 | 3 |
17 | 0 | NP | NEG | Endometrium | SCA + ENAdCA | 3 | 3 |
18 | 0 | NP | NEG | Ovary | SCA + ENAdCA | 3 | 3 |
19 | 1+ | 1.7 | NEG | Endometrium | SCA + ENAdCA | 3 | 3 |
20a | 0–3+ | 1.14 | NEG | Endometrium | SCA + ENAdCA | 3 | 3 |
21 | 0 | NP | NEG | Ovary | SCA + ENAdCA | 3 | 3 |
22 | 1+ | 1.2 | NEG | Endometrium | SCA + ENAdCA | 3 | 3 |
23 | 0 | 1.04 | NEG | Ovary | SCA + ENAdCA | 3 | 3 |
24 | 1+ | 1 | NEG | Ovary | SCA + ENAdCA | 3 | 3 |
25 | 1+ | 1 | NEG | Ovary | SCA + ENAdCA + Mu | 3 | 3 |
26 | 0 | 1 | NEG | Endometrium | ENAdCA + Mu | 1 | 1 |